Literature DB >> 9447860

Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations.

T A Bowdle1, A D Radant, D S Cowley, E D Kharasch, R J Strassman, P P Roy-Byrne.   

Abstract

BACKGROUND: Ketamine has been associated with a unique spectrum of subjective "psychedelic" effects in patients emerging from anesthesia. This study quantified these effects of ketamine and related them to steady-state plasma concentrations.
METHODS: Ketamine or saline was administered in a single-blinded crossover protocol to 10 psychiatrically healthy volunteers using computer-assisted continuous infusion. A stepwise series of target plasma concentrations, 0, 50, 100, 150, and 200 ng/ml were maintained for 30 min each. After 20 min at each step, the volunteers completed a visual analog (VAS) rating of 13 symptom scales. Peripheral venous plasma ketamine concentrations were determined after 28 min at each step. One hour after discontinuation of the infusion, a psychological inventory, the hallucinogen rating scale, was completed.
RESULTS: The relation of mean ketamine plasma concentrations to the target concentrations was highly linear, with a correlation coefficient of R = 0.997 (P = 0.0027). Ketamine produced dose-related psychedelic effects. The relation between steady-state ketamine plasma concentration and VAS scores was highly linear for all VAS items, with linear regression coefficients ranging from R = 0.93 to 0.99 (P < 0.024 to P < 0.0005). Hallucinogen rating scale scores were similar to those found in a previous study with psychedelic doses of N,N-dimethyltryptamine, an illicit LSD-25-like drug.
CONCLUSIONS: Subanesthetic doses of ketamine produce psychedelic effects in healthy volunteers. The relation between steady-state venous plasma ketamine concentrations and effects is highly linear between 50 and 200 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9447860     DOI: 10.1097/00000542-199801000-00015

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  81 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 2.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

3.  The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

Authors:  J P van der Post; S J de Visser; M L de Kam; M Woelfler; D C Hilt; J Vornov; E S Burak; E Bortey; B S Slusher; T Limsakun; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

4.  KETAMINE AS A POSSIBLE MODERATOR OF HYPNOTIZABILITY: A FEASIBILITY STUDY.

Authors:  David R Patterson; Christine Hoffer; Mark P Jensen; Shelley A Wiechman; Sam R Sharar
Journal:  Int J Clin Exp Hypn       Date:  2018 Jul-Sep

5.  Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.

Authors:  Eric J Lenze; Nuri B Farber; Evan Kharasch; Julie Schweiger; Michael Yingling; John Olney; John W Newcomer
Journal:  World J Biol Psychiatry       Date:  2016-02-26       Impact factor: 4.132

6.  The effect of target-controlled infusion of low-dose ketamine on heat pain and temporal summation threshold.

Authors:  Joon-Ho Lee; Sung-Hwan Cho; Sang-Hyun Kim; Won-Soek Chae; Hee-Cheol Jin; Jeong-Seok Lee; Yong-Ik Kim
Journal:  J Anesth       Date:  2011-04-22       Impact factor: 2.078

7.  Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Authors:  Lawrence P Carter; Bethea A Kleykamp; Roland R Griffiths; Miriam Z Mintzer
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

8.  First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.

Authors:  Priska Kaufmann; Marion Ort; Georg Golor; Rüdiger Kornberger; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335

9.  The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Authors:  Xia Chen; Gabriël Jacobs; Marieke de Kam; Judith Jaeger; Jaakko Lappalainen; Paul Maruff; Mark A Smith; Alan J Cross; Adam Cohen; Joop van Gerven
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

10.  Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.

Authors:  Zheng Guan; Linda E Klumpers; Olubukayo-Opeyemi Oyetayo; Jules Heuberger; Joop M A van Gerven; Jasper Stevens
Journal:  Br J Clin Pharmacol       Date:  2016-01-29       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.